FFR narrows cost gap by limiting repeat revascularization, data show

08/26/2013 | TCTMD.com

Although PCI initially carries higher costs than medical therapy alone for patients with abnormal fractional flow reserve, the difference narrows considerably when first-year follow-up costs are considered, according to FAME 2 data. The study of more than 1,200 patients with stable coronary artery disease and angiographically significant stenoses found those treated with PCI were less likely to need repeat revascularization. Experts said assessing FFR allows clinicians to zero in on functionally significant lesions, and appropriate use criteria should be updated accordingly.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN